This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.

You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/health/6221740.stm

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
Sea squirt drug 'treats cancer' Sea squirt drug 'treats cancer'
(about 9 hours later)
A drug made from the sea squirt may help those with a form of cancer, a study in the Lancet suggests. A drug made from the sea squirt may help those with a form of cancer, a study in The Lancet Oncology suggests.
Just over half of a study of 51 patients with a type of soft tissue sarcoma responded positively to treatment with the drug Trabectedin.Just over half of a study of 51 patients with a type of soft tissue sarcoma responded positively to treatment with the drug Trabectedin.
Two patients treated with the drug saw their tumours disappear completely, while others saw their tumours shrink.Two patients treated with the drug saw their tumours disappear completely, while others saw their tumours shrink.
Soft tissue sarcoma is a rare form of cancer, and the type examined in the study represents just 10% of the cases.Soft tissue sarcoma is a rare form of cancer, and the type examined in the study represents just 10% of the cases.
Lead researcher Federica Grosso said the drug could not be used to treat other soft tissue cancers, but she said for those with myxoid liposarcomas the drug offered hope.Lead researcher Federica Grosso said the drug could not be used to treat other soft tissue cancers, but she said for those with myxoid liposarcomas the drug offered hope.
Microbes that live within the sea squirt produce certain compounds which have been extracted to produce the drug.Microbes that live within the sea squirt produce certain compounds which have been extracted to produce the drug.
Sea hopeSea hope
All patients were treated solely with Trabectedin.All patients were treated solely with Trabectedin.
At six months, nearly 90% of those surveyed had not seen their tumours grow, and the median period before the tumours started to grow again was 14 months - a great improvement on other treatment outcomes, researchers said.At six months, nearly 90% of those surveyed had not seen their tumours grow, and the median period before the tumours started to grow again was 14 months - a great improvement on other treatment outcomes, researchers said.
"If the results of this analysis are reproduced in ongoing prospective studies, myxoid sarcoma would represent a uniquely sensitive subgroup to Trabectedin treatment in the heterogeneous family of soft tissue sarcoma," the authors wrote."If the results of this analysis are reproduced in ongoing prospective studies, myxoid sarcoma would represent a uniquely sensitive subgroup to Trabectedin treatment in the heterogeneous family of soft tissue sarcoma," the authors wrote.
Dr Grosso added that they did not yet know why it worked, and that further investigation was needed.Dr Grosso added that they did not yet know why it worked, and that further investigation was needed.
About 1,350 soft tissue sarcomas, lumps which can develop in any of the soft connective tissues of the body, are diagnosed each year in the UK, compared for instance to over 42,000 breast cancers.About 1,350 soft tissue sarcomas, lumps which can develop in any of the soft connective tissues of the body, are diagnosed each year in the UK, compared for instance to over 42,000 breast cancers.
Myxoid sarcomas, which tend to be found in older patients, would account for around 135 of these cases.Myxoid sarcomas, which tend to be found in older patients, would account for around 135 of these cases.
Dr Emma Knight, science information manager at Cancer Research UK, said: "This early-stage research highlights the potential of tapping into Nature's resources for future cancer treatments.Dr Emma Knight, science information manager at Cancer Research UK, said: "This early-stage research highlights the potential of tapping into Nature's resources for future cancer treatments.
"A much larger trial that compares two groups of patients - one treated with the drug and one not - will now be key to proving whether the humble sea squirt really can offer hope to people with cancer.""A much larger trial that compares two groups of patients - one treated with the drug and one not - will now be key to proving whether the humble sea squirt really can offer hope to people with cancer."